Walid Abi-Saab Sells 30,000 Shares of uniQure (NASDAQ:QURE) Stock

Posted by Francis Steltz on Jul 2nd, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report) insider Walid Abi-Saab sold 30,000 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the transaction, the insider owned 148,235 shares in the company, valued at approximately $6,881,068.70. This trade represents a 16.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Walid Abi-Saab also recently made the following trade(s):

On Friday, June 26th, Walid Abi-Saab sold 1,434 shares of uniQure stock. The stock was sold at an average price of $46.86, for a total transaction of $67,197.24.
On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The shares were sold at an average price of $25.06, for a total transaction of $1,127,700.00.

uniQure Stock Performance

QURE traded down $3.36 during mid-day trading on Thursday, reaching $41.81. 2,806,126 shares of the company traded hands, compared to its average volume of 2,743,461. The company’s fifty day moving average price is $29.56 and its 200-day moving average price is $23.58. The stock has a market capitalization of $2.64 billion, a P/E ratio of -12.01 and a beta of 0.90. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, sell-side analysts expect that uniQure N.V. will post -3.63 EPS for the current year.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its position in shares of uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of uniQure by 6.0% during the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 627 shares during the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares during the last quarter. FNY Investment Advisers LLC grew its position in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares in the last quarter. Finally, CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the third quarter worth about $50,000. Institutional investors own 78.83% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

Positive Sentiment: HC Wainwright raised earnings estimates across several years and maintained a Buy rating with an $80 price target, reinforcing bullish long-term expectations for uniQure. Article Title
Positive Sentiment: Zacks said uniQure is trading above a golden cross, a technical pattern that can attract momentum buyers. Article Title
Neutral Sentiment: A market article compared uniQure with Viridian Therapeutics, which may have prompted some relative-value interest but does not appear to reflect a company-specific catalyst. Article Title
Negative Sentiment: Insider Walid Abi-Saab sold shares again, which can pressure sentiment even though the sale was modest in size. Article Title

Analyst Upgrades and Downgrades

QURE has been the subject of a number of recent research reports. Royal Bank Of Canada boosted their price target on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Barclays raised shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $25.00 to $65.00 in a report on Thursday, June 18th. HC Wainwright boosted their target price on shares of uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Monday. Finally, Chardan Capital boosted their target price on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Twelve investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.17.

View Our Latest Report on QURE

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.